EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia

Mohamed El-Tanani, Hamdi Nsairat, Ismail I Matalka, Yin Fai Lee, Manfredi Rizzo, Alaa A Aljabali, Vijay Mishra, Yachana Mishra, Altijana Hromić-Jahjefendić, Murtaza M Tambuwala

Pathology - Research and Practice · 2024-02 · 254 · 155161

DOI: 10.1016/j.prp.2024.155161 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pathology - Research and Practice, 2024-02. Verfasst von Mohamed El-Tanani und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates; Pharmacological and Diagnostic Rese…. Hauptthemen laut MEDLINE: Genes, abl, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic Myeloid Leukemia (CML) is characterized by chromosomal aberrations involving the fusion of the BCR and ABL genes on chromosome 22, resulting from a reciprocal translocation between chromosomes 9 and 22. This fusion gives rise to the oncogenic BCR-ABL, an aberrant tyrosine kinase identified as Abl protein. The Abl protein intricately regulates the cell cycle by phosphorylating protein tyrosine residues through diverse signaling pathways. In CML, the BCR-ABL fusion protein disrupts the first exon of Abl, leading to sustained activation of tyrosine kinase and resistance to deactivation mechanisms. Pharmacological interventions, such as imatinib, effectively target BCR-ABL's tyrosine kinase activity by binding near the active site, disrupting ATP binding, and inhibiting downstream protein phosphorylation. Nevertheless, the emergence of resistance, often attributed to cap structure mutations, poses a challenge to imatinib efficacy. Current research endeavours are directed towards overcoming resistance and investigating innovative therapeutic strategies. This article offers a comprehensive analysis of the structural attributes of BCR-ABL, emphasizing its pivotal role as a biomarker and therapeutic target in CML. It underscores the imperative for ongoing research to refine treatment modalities and enhance overall outcomes in managing CML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genes, ablLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHumansImatinib MesylatePyrimidinesPiperazinesBenzamidesDrug Resistance, NeoplasmFusion Proteins, bcr-ablProtein Kinase Inhibitors

Stichwörter der Autor:innen

BCR-ABLBiomarkersCMLOncogenes

Substanzen

Imatinib MesylatePyrimidinesPiperazinesBenzamidesFusion Proteins, bcr-ablProtein Kinase Inhibitors

Autor:innen und Institutionen

  • College of Pharmacy, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates; Pharmacological and Diagnostic Research Center, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman 1…
  • Pharmacological and Diagnostic Research Center, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman 19328, Jordan.
  • Ras Al Khaimah Medical and Health Sciences University, United Arab Emirates; Department of Pathology and Microbiology, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan.
  • Neuroscience, Psychology & Behaviour, College of Life Sciences, University of Leicester, Leicester LE1 9HN, UK; School of Life Sciences, Faculty of Science and Engineering, Anglia Ruskin University, Cambridge CB1 1PT, U…
  • Department of Health Promotion, Mother and Childcare, Internal Medicine and Medical Specialties, School of Medicine, University of Palermo, Palermo, Italy.
  • Department of Pharmaceutics and Pharmaceutical Technology, Yarmouk University, Irbid 21163, Jordan.

Zitieren

APA

El-Tanani, M., Nsairat, H., Matalka, I. I., Lee, Y. F., Rizzo, M., Aljabali, A. A., Mishra, V., Mishra, Y., Hromić-Jahjefendić, A., & Tambuwala, M. M. (2024). The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia. Pathology - Research and Practice, 254, 155161. https://doi.org/10.1016/j.prp.2024.155161

Vancouver

El-Tanani M, Nsairat H, Matalka II, Lee YF, Rizzo M, Aljabali AA, et al. The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia. Pathology - Research and Practice. 2024;254:155161. doi:10.1016/j.prp.2024.155161

BibTeX
@article{ElTanani2024,
  author = {El-Tanani, Mohamed and Nsairat, Hamdi and Matalka, Ismail I and Lee, Yin Fai and Rizzo, Manfredi and Aljabali, Alaa A and Mishra, Vijay and Mishra, Yachana and Hromić-Jahjefendić, Altijana and Tambuwala, Murtaza M},
  title = {The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia},
  journal = {Pathology - Research and Practice},
  year = {2024},
  volume = {254},
  pages = {155161},
  doi = {10.1016/j.prp.2024.155161}
}
Kostenlos starten →